Saniona AB (publ) (FRA:30S)

Market Cap	147.74M -2.9%
Revenue (ttm)	39.12M +26.8%
Net Income	20.01M +1.2%
EPS	0.15 -16.4%
Shares Out	n/a
PE Ratio	7.38
Forward PE	28.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.041
Previous Close	1.021
Day's Range	1.041 - 1.041
52-Week Range	0.996 - 2.575
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the trea...

• Industry: Pharmaceutical Preparations
• Founded: 2011
• Employees: 43
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30S

Financial Performance

In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error